Prescribing Information can be found at the bottom of this page.
KLISYRI® is a novel inhibitor of tubulin polymerisation that induces cell cycle arrest and, ultimately, apoptotic death of proliferating cells1-3
These events promote a potent antiproliferative effect resulting in clearance of the lesions through mainly mild or moderate local skin reactions (LSRs) which are resolving spontaneously1-4
References
1. KLISYRI SmPC. 2. Niu L, Yang J, Yan W, et al. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of -tubulin explains KXO1’s low clinical toxicity. J Biol Chem. 2019;294(48):18099-18108. 3. Blauvelt A, Kempers S, Schlesinger T, et al. Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 2020;4(6):s121. 4. Kempers S, DuBois J, Forman S, et al. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. J Drugs Dermatol. 2020;19(11):1093-1100.
